CAS 125961-82-2
:Tipelukast
Description:
Tipelukast is a chemical compound classified as a leukotriene receptor antagonist, primarily used in the management of asthma and allergic rhinitis. It functions by inhibiting the action of leukotrienes, which are inflammatory mediators that contribute to bronchoconstriction and mucus production. The molecular structure of Tipelukast includes a specific arrangement of carbon, hydrogen, nitrogen, and oxygen atoms, which contributes to its pharmacological properties. It is typically administered orally and is known for its relatively favorable safety profile, with common side effects being mild and transient. The compound is designed to provide relief from respiratory symptoms by reducing inflammation and improving airflow in the lungs. As with other medications in its class, it is important for patients to follow prescribed dosages and consult healthcare providers regarding potential interactions with other medications or underlying health conditions. Overall, Tipelukast represents a targeted approach in the treatment of respiratory conditions, emphasizing the importance of leukotriene modulation in therapeutic strategies.
Formula:C29H38O7S
Synonyms:- 4-[6-Acetyl-3-[3-[(4-Acetyl-3-Hydroxy-2-Propylphenyl)Sulfanyl]Propoxy]-2-Propylphenoxy]Butanoic Acid
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 7 products.
Butanoic acid, 4-[6-acetyl-3-[3-[(4-acetyl-3-hydroxy-2-propylphenyl)thio]propoxy]-2-propylphenoxy]-
CAS:Formula:C29H38O7SColor and Shape:SolidMolecular weight:530.6728Tipelukast
CAS:Controlled Product<p>Applications Tipelukast a novel oral anti-inflammatory agent, suppresses bladder hyperactivity in a rat model.<br>References Rajasekaran, M., et. al.: BJU Int., 98, 430 (2006)<br></p>Formula:C29H38O7SColor and Shape:NeatMolecular weight:530.67Tipelukast
CAS:Controlled Product<p>Tipelukast is a drug that blocks the action of histamine and leukotrienes by binding to the receptors for these substances. Tipelukast is used in the treatment of asthma, allergic rhinitis, and chronic idiopathic urticaria. It has been shown to be effective in reducing inflammation in a number of animal models including rat models of bladder disease, and rat models of inflammatory bowel disease. Tipelukast can be administered orally with few side effects.</p>Formula:C29H38O7SPurity:Min. 95%Molecular weight:530.67 g/molTipelukast
CAS:<p>Tipelukast (KCA 757), an oral drug for asthma research, blocks leukotrienes and fights inflammation and fibrosis.</p>Formula:C29H38O7SPurity:>99.99%Color and Shape:SolidMolecular weight:530.67
![Butanoic acid, 4-[6-acetyl-3-[3-[(4-acetyl-3-hydroxy-2-propylphenyl)thio]propoxy]-2-propylphenoxy]-](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FIN%2Fthumb%2FDA000QLF.jpg&w=3840&q=75)
